Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”
Tumor-associated macrophages (TAMs), long exploited by cancers to evade immune detection, can now be reprogrammed into potent antitumor effectors through cutting-edge viral engineering. In a landmark study published in the Journal for Immunotherapy of Cancer, Zhang et al introduced an innovative ade...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-06-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/6/e012218.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849421462089236480 |
|---|---|
| author | Marc Lecoultre Aya El Helali |
| author_facet | Marc Lecoultre Aya El Helali |
| author_sort | Marc Lecoultre |
| collection | DOAJ |
| description | Tumor-associated macrophages (TAMs), long exploited by cancers to evade immune detection, can now be reprogrammed into potent antitumor effectors through cutting-edge viral engineering. In a landmark study published in the Journal for Immunotherapy of Cancer, Zhang et al introduced an innovative adenovirus, Adv-mSS, that blocks two critical “don’t eat me” signals, CD47 and CD24, used by tumors to paralyze macrophage activity. By converting immunosuppressive TAMs into tumor-engulfing predators and reigniting CD8 T-cell response, Adv-mSS eradicated tumors across multiple preclinical models. This strategy offers a promising avenue for activating both innate and adaptive immunity against cancer and may address key limitations of current immunotherapies. |
| format | Article |
| id | doaj-art-d2e24ad7b05a4093970c7a547f5bcf35 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-d2e24ad7b05a4093970c7a547f5bcf352025-08-20T03:31:27ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-06-0113610.1136/jitc-2025-012218Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”Marc Lecoultre0Aya El Helali11 Faculty of Medicine, University of Geneva, Geneva, SwitzerlandDepartment of Clinical Oncology, Centre of Cancer Medicine, The University of Hong Kong, Hong Kong, Hong KongTumor-associated macrophages (TAMs), long exploited by cancers to evade immune detection, can now be reprogrammed into potent antitumor effectors through cutting-edge viral engineering. In a landmark study published in the Journal for Immunotherapy of Cancer, Zhang et al introduced an innovative adenovirus, Adv-mSS, that blocks two critical “don’t eat me” signals, CD47 and CD24, used by tumors to paralyze macrophage activity. By converting immunosuppressive TAMs into tumor-engulfing predators and reigniting CD8 T-cell response, Adv-mSS eradicated tumors across multiple preclinical models. This strategy offers a promising avenue for activating both innate and adaptive immunity against cancer and may address key limitations of current immunotherapies.https://jitc.bmj.com/content/13/6/e012218.full |
| spellingShingle | Marc Lecoultre Aya El Helali Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” Journal for ImmunoTherapy of Cancer |
| title | Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” |
| title_full | Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” |
| title_fullStr | Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” |
| title_full_unstemmed | Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” |
| title_short | Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors” |
| title_sort | commentary on targeted release of a bispecific fusion protein sirpα siglec 10 by oncolytic adenovirus reinvigorates tumor associated macrophages to improve therapeutic outcomes in solid tumors |
| url | https://jitc.bmj.com/content/13/6/e012218.full |
| work_keys_str_mv | AT marclecoultre commentaryontargetedreleaseofabispecificfusionproteinsirpasiglec10byoncolyticadenovirusreinvigoratestumorassociatedmacrophagestoimprovetherapeuticoutcomesinsolidtumors AT ayaelhelali commentaryontargetedreleaseofabispecificfusionproteinsirpasiglec10byoncolyticadenovirusreinvigoratestumorassociatedmacrophagestoimprovetherapeuticoutcomesinsolidtumors |